THE COST-EFFECTIVENESS OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN CHINESE CITIES

被引：0
|
作者：
Furnback, W. [1 ]
Wang, B. C. M. [1 ]
Zhu, S. [2 ]
Dong, P. [2 ]
机构：
[1] Elysia Grp Ltd, Taipei, NY, Taiwan
[2] Pfizer Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN12
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness of Using 2 vs 3 Primary Doses of 13-Valent Pneumococcal Conjugate Vaccine
    Stoecker, Charles
    Hampton, Lee M.
    Link-Gelles, Ruth
    Messonnier, Mark L.
    Zhou, Fangjun
    Moore, Matthew R.
    [J]. PEDIATRICS, 2013, 132 (02) : E324 - E332
  • [22] Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
    Shen, Kunling
    Wasserman, Matthew
    Liu, Dongdong
    Yang, Yong-Hong
    Yang, Junfeng
    Guzauskas, Greg F.
    Wang, Bruce C. M.
    Hilton, Betsy
    Farkouh, Raymond
    [J]. PLOS ONE, 2018, 13 (07):
  • [23] Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England
    van Hoek, Albert Jan
    Miller, Elizabeth
    [J]. PLOS ONE, 2016, 11 (02):
  • [24] Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Miller, Elizabeth
    Andrews, Nicholas J.
    Waight, Pauline A.
    Slack, Mary P. E.
    George, Robert C.
    [J]. VACCINE, 2011, 29 (49) : 9127 - 9131
  • [25] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV) Versus 10-Valent PCVs in Filipino Infants
    Perdrizet, J.
    Horn, E.
    Nua, W.
    Perez Peralta, J.
    Nailes, J.
    Santos, J.
    Ong-Lim, A.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S118 - S118
  • [26] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [27] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [28] Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea
    Choi, Min-Joo
    Kang, Shin-On
    Oh, Jin-Jeong
    Park, Seong-Beom
    Kim, Min-Ja
    Cheong, Hee-Jin
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1914 - 1922
  • [29] THE COST-EFFECTIVENESS OF THE NEW PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (PCV13) FOR CHILDHOOD AND ADULT VACCINATION IN THE UK
    Patel, R.
    Stoykova, B.
    Lloyd, A. C.
    Willingham, J.
    Hollingsworth, R.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A427 - A427
  • [30] Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants
    Perdrizet, Johnna
    Horn, Emily K.
    Nua, Winniefer
    Perez-Peralta, Judith
    Nailes, Jennifer
    Santos, Jaime
    Ong-Lim, Anna
    [J]. INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2625 - 2642
12345